Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2026
Sara N Lappan, Sean D Davis
Psychedelic-assisted psychotherapy has demonstrated efficacy in treating individual mental health conditions such as addiction, anxiety, depression, and post-traumatic stress disorder. However, current research predominantly focuses on individual experiences, overlooking the relational and systemic factors that influence healing and long-term therapeutic outcomes. This conceptual article...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2026
William E Rosa, Stephanie Napolitano, Natalie Mcandrew et al.
Psilocybin shows encouraging outcomes for patients with cancer and major depressive disorder (MDD). However, there is insufficient evidence on the use of evidence-based psychotherapeutic interventions to consistently guide and standardize psilocybin preparation, dosing, and integration. Meaning-centered psychotherapy (MCP) is a manualized, brief psychotherapeutic intervention that enhances...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2026
Manal Muteb Alanazi, Mohammed M Alqahtani
The neuropsychological effects of psychedelic compounds are well-documented; however, their respiratory activity is less clear. Since respiration is a physiologically significant process and psychedelics have increasingly attracted attention in therapies, assessing the potential effects on respiration is relevant. The present narrative literature review compiled evidence on serotonergic...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2026
Brian S. Barnett, Akhil Anand, Jeremy Weleff et al.
Little is known about the correlates of repeated non-medical lysergic acid diethylamide (LSD) use. Therefore, we aimed to determine the prevalence and correlates of past-year LSD use among people aged 18 years and older in the United States who first used LSD at least 5 years ago. Using data from the 2015-2019 National Survey on Drug Use and Health, we examined the estimated weighted prevalence...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2026
Sharday Mosurinjohn, Richard S. Ascough
5 citations
This article corrects an idea in psychedelic science and culture that the ancient Eleusynian Mysteries used psychedelics, as claimed by Carl Ruck and co-authors in The Road to Eleusis: Unveiling the Secret of the Mysteries (1978), revitalized by Brian Muraresku's The Immortality Key: The Secret History of the Religion with No Name (2020), and popularized by social media heavyweights such as Joe...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2026
Syed F. Rab, Salman S Ahmad, Roman Palitsky et al.
1 citation
Muslims living in the United States (MLUS) are underrepresented in psychedelics research. Despite growing research on psychedelic-assisted mental health care, little is known about its acceptance among MLUS, a population with some history of rejecting mental health services. This study examined whether MLUS' rejection attitudes toward mental health services were related to lower acceptance of...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2026
Veronica Szpak, Samuel Maddams, Amanda Kim et al.
New treatment options are needed to improve outcomes for patients with both opioid use disorder (OUD) and injection-related infections. Psychedelic-assisted therapy (PAT) has been suggested as a potential treatment for substance use disorders (SUD). To address this need, a qualitative study was conducted to understand the attitudes toward PAT from individuals with OUD who have survived...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2026
Jonah Griffin-Stolbach, Hanna Molla, Donald Hedeker et al.
There has been great interest in the use of very low doses of psychedelic drugs like lysergic acid diethylamide (LSD) to improve mood and cognition. However, controlled studies have thus far provided little support for their efficacy. One challenge is that the subjective effects are subtle and on the threshold of detectability, whereas the questionnaires used to assess the drugs' effects were...
Psychedelic medicine (New Rochelle, N.Y.)
December 1, 2025
Joseph Lorenz, Scott Hawkins, Bryan Mccarthy
Griffiths et al.'s recent "Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions" is an important study in the literature on psychedelic medicine and religious experience. In this commentary on the study, we argue: (1) The study design's implicit presupposition of perennialism in its conception of mysticism burdens it with...
Psychedelic medicine (New Rochelle, N.Y.)
August 1, 2025
Kush V. Bhatt, Jason Compton, Em Ellerman et al.
1 citation
Mystical experiences are powerful experiences that may have therapeutic value. Ketamine, a dissociative anesthetic, has shown potential to induce mystical experiences. However, little research has explored this phenomenon, particularly in treatment-resistant depression. We analyzed clinical data from 60 veterans with treatment-resistant depression receiving a total of 189 ketamine treatments....
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Haley Maria Dourron, Melissa Bradley, Otto Simonsson et al.
7 citations
Prior research examining the associations between psychedelic use and general psychotic symptoms has yielded mixed findings. However, no studies have investigated the relationships between psychedelic use and specific psychotic symptoms, and whether these relationships might differ among those with liability to psychosis, namely those with a history of psychotic or bipolar disorders. Using...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Rahul Katkar, Ashley M Perez, Murat Altinay et al.
4 citations
Gender-themed lysergic acid diethylamide (LSD) experiences have been documented anecdotally but not yet studied systematically. This study aimed to explore such experiences using data from Reddit to better understand their nature and potential therapeutic implications. In this retrospective observational study, posts and comments on the "r/LSD" subreddit reporting gender-themed LSD experiences...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Sara Shoar, Alissa Bazinet, Chaitra Jairaj
2 citations
In recent years, there has been a resurgence in research exploring the therapeutic potential of psychedelics for treating mental health disorders, coinciding with increasing psychedelic use and changing legal landscapes in the United States and globally. Despite these shifts, there remains a notable gap in understanding related to the safety of psychedelic use during critical stages of the...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Sierra Carter, Grace Packard, Jessica L Maples-Keller
Black Americans are significantly underrepresented in psychedelic trials despite significant mental health disparities. Growing research suggests that psychedelic-assisted therapy (PAT) is an effective treatment for post-traumatic stress disorder and depression. It is important to understand perceptions of PAT among populations with unmet mental health needs. We conducted four focus groups to...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Olivia M Dhaliwal, Lukas Bobak, Brian S. Barnett
With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedioxymethamphetamine in the treatment of posttraumatic stress disorder, the likelihood of psychedelic medication becoming approved for clinical use in the United States is high. Psychedelic-assisted therapy (PAT) may have a high demand in rural America,...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2025
Daniel J. Kruger, Jacob S. Aday, Christopher W Fields et al.
19 citations
Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2025
Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al.
16 citations
N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew, has shown antidepressant effects. This open-label clinical trial investigates for the first time the efficacy of vaporized DMT in treatment-resistant depression (TRD). Six TRD patients participated in an open-label, fixed-order, dose-escalation study, receiving a lower (15 mg)...
Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2025
Rebecca Ehrenkranz, Manish Agrawal, Sandeep M. Nayak et al.
7 citations
Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In recent years, the public discourse around psychedelic treatments has been largely positive and focused on benefits more than risks. We believe the field would benefit from more balanced attention to the risks as well as benefits of psychedelics...
Psychedelic medicine (New Rochelle, N.Y.)
December 1, 2024
Cianna J Piercey, Bethany A. Gray, Angelina Sung et al.
5 citations
Approximately 8.5 million Americans over the age of 12 endorsed past year psychedelic use in 2022, with 1.4 million individuals initiating use during this time. Although emerging evidence indicates there may be beneficial aspects of psychedelic use, there is a need to understand how individuals might mitigate potential risks within nonclinical contexts, such as through the use of protective...
Psychedelic medicine (New Rochelle, N.Y.)
December 1, 2024
Daniel Markman, Andrzej Z Wasilczuk, Joseph Michael Cichon
2 citations
Psychedelic-induced experiences are thought to play an important role in the therapeutic actions of rapid-acting antidepressants. General anesthesia is one scenario in which patients can be rendered unconscious and masked to the psychedelic treatment, providing a simple yet effective method to examine drug-induced changes in the brain devoid of experiences. Chronically stressed adult C57/BL6...
Psychedelic medicine (New Rochelle, N.Y.)
December 1, 2024
Connor J Haggarty, Hanna Molla, James Glazer et al.
2 citations
Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these doses affect emotional processing in the brain. In this study, we tested the effect of a single low dose of LSD (26 µg) compared with placebo on electroencephalogram (EEG) event-related potentials (ERP: N170, P300 and Mismatch Negativity) in healthy...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2024
Zarmeen Zahid, Ziyad W. Sultan, Bryan M Krause et al.
5 citations
Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that despite having distinct molecular targets, both drugs may exert therapeutic benefit via their pro-neuroplastic effects. Following treatment with ketamine or serotonergic psychedelics, patients are reported to be more open to behavioral change, which...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2024
Carolyn M. Porta, Madison E. Weirick, Anna Graefe et al.
4 citations
To explore nurses' knowledge, attitudes, and perceived social norms about psychedelic use to address mental health conditions. Data were collected through an anonymous e-survey of Minnesota registered nurses, advanced practice registered nurses, and psychiatric-mental health nurse practitioners in Spring 2023; the pool was randomly selected from the Minnesota Board of Nursing registry. A total...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2024
Crystal Lederhos Smith, Nathan Sackett, Brian Connor Stark et al.
4 citations
There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, put in place in 1970. Despite the regulatory difficulty, research has rapidly expanded in the past decade. Multiple states and cities have drafted their own policies regarding the use of psychedelics. Assuming interest in psychedelics continues to...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2024
Michelle St Pierre, Lucas Standing, Yarissa Herman et al.
3 citations
A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of psychedelics for therapeutic purposes (PTPs) has experienced growing attention in the past decade and may be an increasing topic of patient-physician interactions. The stigmatization of psychedelic use may complicate this process. However, patient...